Ningetinib is a selective inhibitor primarily investigated for its role in targeting specific kinase pathways involved in cancer progression. It shows promise in oncology, particularly in the treatment of solid tumors by blocking signaling pathways that drive tumor growth and survival. Its application is being explored in clinical trials for cancers where dysregulated kinase activity plays a key role, such as non-small cell lung cancer and other advanced malignancies. Due to its targeted mechanism, ningetinib may offer improved efficacy with reduced side effects compared to conventional chemotherapy. Research also suggests potential use in overcoming resistance to earlier-generation inhibitors, making it a candidate for combination therapies in precision medicine approaches.